1-3 of 3
Michael Stratford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94

Free
Thomas R. Wittenborn, Michael Stratford, Mary Lynn Trawick, Kevin G. Pinney, David J. Chaplin, Dietmar W. Siemann, Michael R. Horsman
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1816.
https://doi.org/10.1158/1538-7445.AM2014-1816
Published: 01 October 2014
View articletitled, Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94
Journal Articles

Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature

Available to Purchase
Emmanouil Fokas, Jae Hong Im, Sally Hill, Sabira Yameen, Michael Stratford, John Beech, Wolfgang Hackl, Sauveur-Michel Maira, Eric J. Bernhard, W. Gillies McKenna, Ruth J. Muschel
Journal: Cancer Research
Cancer Res (2012) 72 (1): 239–248.
https://doi.org/10.1158/0008-5472.CAN-11-2263
Published: 02 January 2012
View articletitled, Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature
Open the PDF for Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer

Available to Purchase
Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P. Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S. Lewin, Keith R. McCrae, Scot C. Remick
Journal: Cancer Research
Cancer Res (2002) 62 (12): 3408–3416.
Published: 01 June 2002
View articletitled, A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer
Open the PDF for A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer in another window